Research programme: immune disorder therapeutics - LyceraAlternative Names: Bz-423; LYC-53976
Latest Information Update: 16 Jul 2016
At a glance
- Originator Lycera
- Class Antifibrotics; Immunotherapies; Small molecules
- Mechanism of Action Adenosine triphosphatase inhibitors; Adenosine triphosphatase modulators; Helper-inducer T-lymphocyte inhibitors; Rho-associated kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis; Inflammatory bowel diseases
- No development reported Autoimmune disorders